表紙
市場調査レポート

神経幹細胞・前駆細胞製品の戦略的開発

Strategic Development of Neural Stem & Progenitor Cell Products

発行 BIOINFORMANT WORLDWIDE, LLC 商品コード 227599
出版日 ページ情報 英文 113 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.71円で換算しております。
Back to Top
神経幹細胞・前駆細胞製品の戦略的開発 Strategic Development of Neural Stem & Progenitor Cell Products
出版日: 2012年01月04日 ページ情報: 英文 113 Pages
概要

当レポートでは、神経幹細胞および前駆細胞製品の市場について調査分析し、神経幹細胞研究の応用先に関する最新動向、応用先の優先順位、神経幹細胞の各種研究用製品の種類、研究用製品を利用するラボおよびエンドユーザーのプロファイル、特許分析、5ヵ年市場成長予測、研究用製品の主要サプライヤーの競合分析、サプライヤーへのガイダンスなどをまとめ、概略下記の構成でお届けいたします。

第1章 背景

第2章 応用先

  • 基礎研究
  • 創薬
  • ドラッグデリバリー
  • 神経毒性評価
  • 神経移植
  • 脳腫瘍研究

第3章 応用先の優先順位

  • 全体
  • 神経幹細胞研究の疾患別内訳
  • 部門別
    • 学術分野
    • バイオテクノロジー分野
    • 医薬品分野

第4章 特許

第5章 5ヵ年市場成長予測

  • 科学論文の発表
  • 助成率
  • 特許率

第6章 競合企業:神経幹細胞・前駆細胞製品のサプライヤーと提供製品

  • Millipore, Inc.
  • Stem Cell Technologies
  • AlphaGenix, Inc.
  • R&D Systems
  • Cell Applications
  • SA Biosciences
  • ScienCell
  • Neuromics
  • Amaxa
  • Invitrogen
  • Sigma Aldrich
  • Orion(現在は存在しない)

第7章 神経幹細胞・前駆細胞治療の特殊医薬品企業

  • Neuralstem, Inc
  • NeuroNova AB
  • NeuroGeneration

第8章 幹細胞研究の細胞区分別内訳

第9章 神経細胞製品の潜在的エンドユーザー

  • 学術研究ラボ
  • 民間ラボ
  • 商業ラボ
  • 政府系ラボ

第10章 製品のアイデア・提案

  • 製品カテゴリー
    • 細胞・組織
    • キット
    • 各種培地
    • グロースファクター
    • 市場:神経幹細胞・分化子孫市場
    • PCRアレイ
    • Nucleofectionツール
    • 神経毒性分析
  • 製品の提案
    • 神経毒性の分析製品
    • 種に特異な機会
    • 競合の激しくない領域
    • 新しいソース由来の神経幹細胞
    • 神経ロゼット細胞

第11章 総論

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

EXECUTIVE SUMMARY

Neurogenesis is the process by which neurons are created. This process is most active during pre-natal development when neurogenesis is responsible for populating the growing brain. Neural stem cells (NSCs) are the self-renewing, multipotent cells that differentiate into the main phenotypes of the nervous system. These cell types include neurons, astrocytes, and oligodendrocytes. Neural progenitor cells (NPCs) are the progeny of stem cell division that normally undergo a limited number of replication cycles in vivo.

The terms neuronal and neural also need to be defined. Technically speaking, “neuronal” means “pertaining to neurons," and “neural” means “pertaining to nerves, which are the cordlike bundles of fibers made up of neurons.” Since both terms ultimately are descriptive of neurons, the scientific community uses the terms "neuronal" and "neural" interchangeably. The complexity of this issue is explored from a strategic perspective within this report.

In particular, when naming products, companies are advised to use the term “neural” rather than “neuronal,” both in reference to stem cells and progenitor cells, in order to best position products within the marketplace. Also of interest is that when “stem cell” versus “progenitor cell” publications are compared, neural/neuronal “stem cell” publication rates continue to outpace neural/neuronal “progenitor cell” publications by over 200% over a trailing two-year period.

In summary, an understanding of neural stem cell language and terminology can substantially improve product naming, strategic positioning, and the effectiveness of marketing communications. These subtleties as explored in detail within the context of this industry report.

In addition, the report focuses on: recent advances in neural stem cell research applications; research priorities by market segment; opportunities for profitable product and technology development; the competitive environment for NSC products; detailed market size analysis; market trends and metrics; five-year projections; and the needs and decision-making of NSC scientists.

Background

In 1992, Reynolds and Weiss were the first to isolate neural stem cells from the striatal tissue of adult mice brain tissue, including the subventricular zone, which is a neurogenic area. Since then, neural progenitor and stem cells have been isolated from various areas of the adult brain, including non-neurogenic areas like the spinal cord, and from other species, including humans. During the development of the nervous system, neural progenitor cells can either stay in the pool of proliferating undifferentiated cells or exit the cell cycle and differentiate. The past twenty years have seen great advances in neural stem cell research and applications. Researchers have isolated NSCs, which have demonstrated pluripotency and the ability to differentiate into many different immune system cell types. In addition, NSCs can be regulated both in vitro and in vivo, which represent different commercial product opportunities. Neural stem cells have also become of profound interest to the research community due to their potential to be used in drug discovery and delivery applications, as well as for tools of neural toxicology assessment. NSC transplantation also represents a ground-breaking approach for treating a range of chronic neurological diseases and acute CNS injuries, including Parkinson's, Alzheimer's and spinal cord injury, among other conditions.

Furthermore, neural stem and progenitor cells offer the potential to safely carry out pharmacology assessment for drugs designed to impact brain function or physiology. As tests on human cells become increasingly feasible, the potential grows for companies to develop disease-specific cell assays by producing recombinant stem cell lines expressing a therapeutic target. As novel drug delivery agents, neural stem cells also show promise in killing gliomas and other cancers. Finally, viable therapies for treating disease through neural stem cell transplantation are also on the horizon for forward-thinking researchers.

Market Segments

To facilitate research resulting from these advances, a large and diverse market has emerged for neural stem cell products, platforms, and technologies. In total, the neural stem cell product marketplace is comprised of the global sales of these items. One thriving component of this marketplace is the segment of companies that sell NSC research products to scientists.

Termed “research supply companies” or “research product vendors,” large companies selling neural stem cell research products include EMD Millipore, Life Technologies, Thermo Fisher Scientific, and STEMCELL Technologies, as well as more than 40 other suppliers that range in size from multinational corporations to small specialty companies. Together, these research supply companies represent a substantial annual percentage of NSC product sales. Each of these industry participants are identified within the context of this report. As of 2013, EMD Millipore, known as Merck Millipore outside of the United States and Canada, is the leader in neural stem cell product development for the scientific community. A Canadian company, STEMCELL Technologies, is a close second in the area of NSC product development for scientists.

Within this report, profitable opportunities for NSC research product development are revealed. Specifically, competitors looking to enter the NSC research products marketplace would do well to focus their energy on the areas considered highest priority by the scientific community, specifically cell-based therapies and standardized neurotoxicity assays. Due to recent legislative initiatives, interest in the latter is expected to increase significantly in the next several years. Furthermore, companies looking to enter the NSC product market could also focus their efforts on areas in which available products are not yet optimized for use with rat or mouse neural stem cells. Or, research supply companies could choose to focus product development on areas where human neural stem cell products are not yet available, although there would be some necessary work-around due to patent restrictions. Companies could also develop products for which there is little market competition, such as hESC-derived neural progenitors, kits for analysis of NSC differentiated progeny, NSC blotting and nucleofaction kits, and PCR arrays. Finally, companies could choose to explore varied sources from which to potentially derive neural stem cell products, such as human umbilical cord blood and derivatives of neural rosette cell lines.

In addition, pharmaceutical companies also have intense interest in neural stem cell product development. Because of their plasticity, ability to develop into the main phenotypes of the nervous system, and unlimited capacity for self-renewal, NSCs have been proposed for use in a variety of pharmaceutical applications, including:

  • Neurotoxicity testing
  • Cellular therapies to treat central nervous system (CNS) conditions
  • Neural tissue engineering and repair
  • Drug target validation and testing
  • Personalized medicine
  • And more

While development of therapies that involve embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), and mesenchymal stem cells (MSCs) continue to expand, development of neural stem cell therapies has been more substantially affected by barriers to entry, including patent restrictions, the dominance of current competitors, and the complexity of neural stem cell applications. Nonetheless, within the area of NSC therapy development, there are currently three dominant competitors, which are Neural Stem, NeuroNova AB, and NeuroGeneration. In addition to those companies, there are also more than a dozen other companies actively developing NSC therapies for use in the treatment of human injury and disease.

For this reason, development of NSC products by the pharmaceutical sector also represents a thriving segment of the global NSC product marketplace. Of particular interest to this community is the potential for use of NSCs to heal tissues that have a naturally limited capacity for renewal, such human brain and spinal cord tissues.

Furthermore, within the pharmaceutical sector, development of new drugs is extremely costly and the success rate of bringing new compounds to the market is unpredictable. Therefore, it is crucial that pharmaceutical companies minimize late-stage product failures, such as suboptimal pharmacokinetic properties or unexpected neurotoxicity effects, that can can arise when candidate drugs enter the clinical testing stages. To achieve this, it would be highly desirable to test candidate drugs using in vitro assays of high human relevance as early as possible. Because NSCs have the potential to differentiate into nearly all of the main phenotypes of the nervous system, they represent an ideal cell type from which to design such neural screening assays.

In summary, the unifying factor within the NSC product marketplace is that all companies involved need to understand market forces, trends, metrics, and financials, in order to out-compete the competition and make more profitable decisions. Producing NSC products can involve complicated and confusing decisions, but it doesn't have to.

Claim this report to reveal the current and future needs of the NSC marketplace, so you can focus your marketing efforts on the most profitable products, in the most promising research areas, and within the most lucrative domestic and international markets. Your competitors would prefer you didn't buy this report. But when you do, you'll be gaining invaluable stem cell market insights to help you control and dominate this market.

Key Findings Include:

  • Charts, Trends, and Metrics for the NSC Product Market
  • Analysis NSC Grant Rates, Scientific Publication Rates, and Patent Rates
  • Market Size Quantification for NSC Products
  • 5-Year Market Size Projections (2013-2017) for NSC Products
  • Profitable Opportunities for NSC Product and Technology Development
  • Consumer Behavioral Patterns and Preferred Providers
  • Preferred Species for NSC Research
  • Crucial Trends and Unmet Market Needs
  • End-User Survey of NSC Researchers (91 U.S. / 149 International)

To profit from this rapidly expanding market, you need to understand your key strengths relative to the competition, intelligently position your products to fill gaps in the market place, and take advantage of crucial NSC product trends. Claim this must-read industry report to optimally position yourself to sell NSC products.

Table of Contents

I. Background

  • A. Language and Definitions
    • 1. Neurogenesis
    • 2. Neuronal vs. Neural
    • 3. Neural Stem Cells (NSCs) vs. Neural Progenitor Cells (NPCs)
  • B. Brief History
  • C. Overview of Neural Stem and Progenitor Cell Regulation
    • 1. In vitro Regulation
    • 2. In vivo Regulation
  • D. Product Background

II. Applications

  • A. Basic Research
    • 1. Developmental Biology
    • 2. Adult Biology
  • B. Drug Discovery Applications
  • C. Drug Delivery Applications
  • D. Neural Toxicology Assessment
  • E. Neural Transplantation
  • F. Brain Tumor Research

III. Application Priorities

  • A. Overall
    • 1. Cell-Based Therapies
    • 2. Standardized Neural Toxicology Assays
  • B. Breakdown of Neural Stem Cell Research by Disorder
  • C. By Segment
    • 1. Academic
    • 2. Biotech
    • 3. Pharma

IV. Patents

  • A. Key U.S. Neuronal Stem and Progenitor Cell Patents
  • B. Additional U.S. Patents
  • C. Additional European Patents

V. Projected 5-Year Market Growth

  • A. Scientific Publication Analysis
    • 1. Neural vs. Neuronal Products
    • 2. Stem vs. Progenitor Cell Products
    • 3. Five-Year Growth Projections
    • 4. Conclusions from Data
  • B. Grant Rate Analysis
    • 1. Neural vs. Neuronal Products
    • 2. Stem vs. Progenitor Cell Products
    • 3. Five-Year Growth Projections
    • 4. Conclusions from Data
  • C. Patent Rate Analysis
    • 1. Neural vs. Neuronal Products
    • 2. Stem vs. Progenitor Cell Products
    • 3. Five-Year Growth Projections
    • 4. Conclusions from Data

VI. Competitors: Suppliers of Neural Stem & Progenitor Cell Products, Including Products Offered

  • A. Millipore, Inc.
  • B. Stem Cell Technologies
  • C. AlphaGenix, Inc.
  • D. R&D Systems
  • E. Cell Applications
  • F. SA Biosciences
  • G. ScienCell
  • H. Neuromics
  • I. Amaxa
  • J. Invitrogen
  • K. Sigma Aldrich
  • L. Orion (no longer in existence)

VII. Specialty Pharmaceutical Companies: Neural Stem & Progenitor Cell Therapies

  • A. Neuralstem, Inc
  • B. NeuroNova AB
  • C. NeuroGeneration

VIII. Breakdown of Stem Cell Research Activity by Cell Type

IX. Potential End-Users of Neural Stem Cell Products

  • A. Academic Labs
  • B. Private Labs
  • C. Commercial Labs
  • D. Government Labs

X. Product Ideas & Suggestions

  • A. Product Categories
    • 1. Cells & Tissue
      • a. Fetal-Derived Neural Stem Cells
      • b. Adult-Derived Neural Stem Cells
      • c. Fetal-Derived Immortalized Neural Stem Cells
      • d. Cryopreserved Embryonic Neurospheres
      • e. Embryonic Stem Cell Derived Neural Progenitors
      • f. Embryonic Primary Neuronal Tissue
      • g. NSC Differentiated Progeny Cells
    • 2. Kits
      • a. Kits for Analysis of NSC Differentiated Progeny
      • b. Stem Cell Functional Kits
      • c. Neuronal Stem Cell Phenotyping Kits
      • d. Neural Stem Cell Expansion Kits
      • e. Neural Stem Cell Differentiation Kits
      • f. Neural Stem Cell Blotting Kits
    • 3. Media: Maintenance, Differentiation, Expansion, & Freezing Medium
    • 4. Growth Factors
    • 5. Markets: Markers for Neural Stem Cells & Differentiated Progeny
    • 6. PCR Arrays
    • 7. Nucleofection Tools
    • 8. Neural Toxicity Assessment
  • B. Product Suggestions
    • 1. Neural Toxicity Assessment Products (an untapped niche)
    • 2. Species-Specific Opportunities
    • 3. Areas of Underdeveloped Competition
    • 4. NSC Derived from Novel Sources
    • 5. Neural Rosette Cells (R-NSCs)

XI. Conclusions

Back to Top